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ABSTRACT
Objectives:  We aimed to evaluate comorbidities and their 
association with clinical parameters in  patients with ankylosing 
spondylitis (AS). 
Patients and Methods:  A hundred and ten  AS patients were 
included. Disease activity was evaluated by Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI), functional status 
by Bath Ankylosing Spondylitis Functional Index (BASFI), spinal 
mobility Bath Ankylosing Spondylitis Metrology Index (BASMI) 
and quality of life by Nottingham Health Profile (NHP).  
Results:  Comorbidities were detected in 28.18% of the 
patients. These were peptic ulcer (20.91%), hypertension (20%), 
lung disease (15.45%), diabetes mellitus (13.64%), osteoporosis 
(10.91%), ischemic heart disease (10%), renal diseases (Ig A 
nephropathy and renal papillary necrosis, 1.82%) and cancers 
(papillary thyroid carcinoma and renal cell ca, 1.82%), respectively. 
Patients with comorbidities scored significantly higher in BASDAI, 
BASMI, BASFI, VAS-pain, and pain, physical mobility, and 
energy subgroups of NHP (p<0.05). Peripheral involvement was 
observed in 27.27% of the patients. The frequency of comorbidities 
was higher in the patients with peripheral involvement (Pearson 
X2=54.725, p<0.01).
Conclusion: Comorbid  conditions of AS are associated with 
more active disease, functional impairment and deterioration in 
quality of life. Therefore, comorbidities should be detected and 
treated earlier in order to reduce their negative impact on disease 
outcome. 
Keywords: Ankylosing spondylitis, Comorbidity, Disease activity, 
Quality of life
ÖZ
Amaç: Ankilozan spondilit (AS) hastalarındaki komorbiditeleri ve 
klinik parametrelerle ilişkisini değerlendirmeyi amaçladık.
Hastalar  ve Yöntem: Çalışmaya 110 AS hastası dahil edildi. 
Hastalık aktivitesi Bath Ankilozan Spondilit Hastalık Aktivite 
İndeksi [Bath Ankylosing Disease Activity Index (BASDAI)] ile, 
fonksiyonel durum Bath Ankilozan Spondilit Fonksiyonel İndeks 
[Bath Ankylosing Spondylitis Functional Index (BASFI)] ile, 
spinal mobilite Bath Ankilozan Spondilit Metroloji İndeksi [Bath 
Ankylosing Spondylitis Metrology Index (BASMI)] ile ve yaşam 
kalitesi ise Nottingham Sağlık Profili [Nottingham Health Profile 
(NHP)] ile değerlendildi. 
Bulgular: Hastaların %28,18’inde komorbidite saptandı. 
Bunlar sırası ile peptik ülser (20,91%), hipertansiyon (%20), akciğer 
hastalığı (%15,45), diabetes mellitus (%13,64), osteoporoz 
(%10,91), iskemik kalp hastalığı (%10), böbrek hastalıkları 
(Ig A nefropatisi ve renal papiller nekroz, %1,82) ve kanserler 
(papiller tiroid kanseri ve renal hücreli kanser, %1,82) idi. 
Komorbiditesi bulunan hastalar BASDAI, BASMI, BASFI, 
VAS-ağrı ve NHP’nin ağrı, fiziksel mobilite ve enerji alt 
gruplarında belirgin olarak yüksek skorlama gösterdiler 
(p<0,05). Periferik tutulum hastaların %27,27’sinde gözlendi. 
Komorbidite sıklığı periferik tutulumlu hastalarda daha fazlaydı 
(Pearson X2=54,725, p<0,01).
Sonuç: AS’nin komorbid durumları,  daha aktif hastalık, 
fonksiyonel kısıtlılık ve yaşam kalitesinde bozulma ile ilişkilidir. 
Bu neden ile  hastalık sonuçlarına olumsuz etkileri azaltmak için 
bu komorbiditelerin erken tespit edilip tedavi edilmesi gereklidir. 
Anahtar kelimeler: Ankilozan spondilit, Komorbidite, Hastalık 
aktivitesi, Yaşam kalitesi 
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Introduction
Ankylosing spondylitis (AS) is a common 
inflammatory rheumatic disease which belongs to the 
spondyloarthritis group. It affects the axial skeleton, causing 
characteristic inflammatory back pain [1]. Peripheral joint 
involvement usually appears in lower extremities. Peripheral 
involvement which occurs in the early stages of the disease 
predicts more aggressive disease [2].
Patients with AS frequently suffer from comorbidities [3]. 
Comorbidities may either be linked to the disease process, 
to the treatment, or may be an independent finding and 
they contribute to the burden of the disease. Hypertension, 
ischemic heart diseases, diabetes mellitus and osteoporosis 
have been found to be increased in people with AS [4]. 
Health-related quality of life (HRQoL) is defined as 
“individuals’ perception of their position in life in the 
context of the culture and value systems in which they live 
and in relation to their goals, expectations, standards and 
concerns” by World Health Organization [5]. HRQoL is an 
outcome measure that is increasingly being used to evaluate 
health outcome in clinical studies of patients with rheumatic 
disorders including AS [6]. Comorbidities in rheumatic 
disorders lead to functional impairment, worse HRQoL 
and mortality [7]. They add to the complexity of diagnosis, 
prognosis and treatment of the disease. Understanding the 
natural course, causes and impacts of comorbidities will 
help us in the treatment and management of the disease [8].
The main objectives of the present study were i) to 
examine the comorbidities in Turkish patients with AS; ii) to 
assess the association between peripheral involvement and 
presence of comorbidities and; iii) to evaluate the impact 
of comorbidities on HRQoL in terms of disease activity, 
functional status, severity of pain, and social and emotional 
functioning.  
Patients and Methods
A total of 110 AS patients  (75 males and 35 females) followed 
at outpatient physical medicine and rehabilitation and 
rheumatology clinics of two training and research hospitals 
were included in the study. All of the patients fulfilled the 
modified New York criteria [9]. Patients were evaluated by 
using Assessment of SpondyloArthritis International Society 
(ASAS) recommendations for core outcome domains for 
the assessment in AS [10]. Patient data regarding age, 
gender,  body mass index (BMI), duration of the disease and 
history of peripheral involvement were recorded. Peripheral 
involvement was accepted as pain, swelling or limitations 
of peripheral joints. Patients were asked to complete the 
questionnaire regarding the comorbidities such as ischemic 
heart disease, hypertension, diabetes mellitus, osteoporosis, 
peptic ulcer, osteoporosis, lung diseases, renal diseases and 
cancers, and then presence of comorbidities was confirmed 
by the data extracted from patient records. Patient records 
comprised serum biochemistry tests; echocardiography 
and electrocardiogram, chest x-ray and thoracic computed 
tomography; upper gastrointestinal endoscopy; dual-energy 
x-ray absorptiometry (DEXA) and physical examination 
reports regarding the comorbidities. Erythrocyte 
sedimentation rate (ESR, mm/hour) was measured by 
Westergren tube method and C-reactive protein (CRP, mg/
dl) by nephelometric method. 10 cm Visual Analog Scale-
Pain (VAS-pain) was used to determine the severity of 
pain [11].  Disease activity was evaluated by using Turkish 
version of Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI) [12]. The Bath Ankylosing Spondylitis 
Functional Index (BASFI) was used for determining 
functional status [13]. HRQoL was assessed by using 
Nottingham Health Profile (NHP) [14]. Spinal mobility 
was measured by using The Bath Ankylosing Spondylitis 
Metrology Index (BASMI) [15]. 
Written informed consent was signed by all of the 
patients. Medical Research Ethics Committee approved the 
study protocol. Our study conforms to the provisions of the 
World Medical Association’s Declaration of Helsinki.
Statistical Analyses
Descriptive statistics [mean, median, SD (Standard 
deviation), minimum, maximum and frequencies] were used 
for assessing the demographics and clinical parameters. 
Differences between patients with and without comorbidities 
were assessed using independent samples T-test. Differences 
between patients with and without peripheral arthritis were 
evaluated using chi-square test. Logistic regression analysis 
was used to determine the effects of age, gender and BMI 
on comorbidities.  A value of   p <0.05 was considered 
statistically significant. All analyses were performed using 
IBM Statistical Package for the Social Sciences (SPSS) for 
Windows, Version 21.0 (Armonk, New York, USA).
Results
Sociodemographic characteristics 
 A total of 110 AS patients (75 males and 35 females) were 
included in the study.  Male-female ratio was 2.14. Mean 
age was 40.38±9.83 (21-71). Mean disease duration was 
11.42±7.86 (1-36) years. Mean BMI was 30.10±4.08 (19-
39). Mean value was 25.47±18.96 for ESR, 20.90±14.22 for 
CRP, and 5.06±3.19 for VAS-pain.
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Comorbidities
Comorbidities were reported in 31 patients (28.18%). The 
most common was peptic ulcer (23 patients, 20.91%). This 
was followed by hypertension (22 patients, 20%), lung 
disease (17 patients, 15.45%), diabetes mellitus (15 patients, 
13.64 %), osteoporosis (12 patients, 10.91%), ischemic 
heart disease (11 patients, 10%), renal diseases [2 patients 
(Ig A nephropathy and renal papillary necrosis), 1.82%) and 
cancers [2 patients (papillary thyroid carcinoma and renal 
cell ca), 1.82%], respectively (Table I).
Table I.  Prevalence of comorbidities in 110 AS patients (n=50)
Comorbidities Number 
(percentage)
Peptic ulcer 23 (20.91)
Hypertension 22 (20)
Lung diseases (asthma, chronic obstructive 
pulmonary disease)
17 (15.45)
Diabetes mellitus 15 (13.64)
Osteoporosis 12 (10.91)
Ischemic heart disease 11 (10)
Renal disease 2 (1.82)
Cancers 2 (1.82)
Patients with comorbidities scored significantly higher 
in BASDAI, BASMI, BASFI, VAS-pain, and in the pain, 
physical mobility, and energy subgroups of NHP (p<0.05) 
(Table II).
Table II. The relation between presence of comorbidities and 
clinical parameters
Comorbidities
Present
(n=50)
Absent
(n=60)
P value
BASDAI 5.05±2.08 3.67±1.38 0.003**
BASMI 4.27±2.43 3.23±2.34 0.044*
BASFI 5.75±2.06 2.40±1.72 <0.001**
VAS-pain 6.86±2.24 3.59±3.01 <0.001**
NHP-pain 54.41±27.15 43.34±29.28 0.043*
NHP-physical mobility 46.00±30.77 32.7±30.72 0.026*
NHP- energy 52.00±40.35 30.33±36.83 0.004**
NHP- sleep 42.4±30.94 33.44±30.71 0.13
NHP-social isolation 38.4±33.28 28.52±27.08 0.91
NHP-emotional 
reactions
40.85±35.17 35.24±31.83 0.381
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, BASMI: 
Bath Ankylosing Spondylitis Metrology Index, BASFI: Bath Ankylosing 
Spondylitis Functional Index, VAS: Visual Analog Scale, NHP: 
Nothingham Health Profile, *: p < 0.05 (significant), **: p < 0.01 (highly 
significant)
Peripheral joint involvement
Peripheral involvement was reported in 27.27% of the 
patients (30 patients) during the disease course. Of all these 
cases, 66.67% the hips (20 patients), in 56.67% the knees 
(17 patients), in 10% the shoulders (3 patients) and in 6.67% 
the ankles (2 patients) were affected. 
The frequency of comorbidities was higher in the patients 
with peripheral involvement as compared to the patients 
without peripheral involvement (Pearson X2=54.725, 
p<0.01) (Table III). 
Table III. The relation between presence of peripheral arthritis and 
comorbidities
Comorbidities P value
absent present total
Peripheral 
arthritis
absent 73 7 80 <0.0001**
present 6 24 30 
total 79 31 110
Pearson chi-square=54.725 , **: p < 0.01 (highly significant)
Impact of age, gender and BMI on comorbidities
Multiple regression analysis revealed no impact of age, 
gender or BMI on comorbidities (p >0.05).  β coefficients 
and adjusted R2 values are given in Table IV. 
Table IV. Impact of age, gender and BMI on comorbidities in the 
patients with AS 
Presence of comorbidities
(Adjusted R2:0.064)
Variables β P value
Age 0.012 0.009
Gender 0.008 0.928
BMI 0.002 0.863
BMI: Body mass index
Discussion 
Our study demonstrates that AS is associated with a 
high prevalence of comorbidities. We found the rate of 
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comorbidities as 28.18%. The most common comorbidities 
were peptic ulcer (20.91%), hypertension (20%) and lung 
diseases (15.45%). Diabetes mellitus (13.64 %), osteoporosis 
(10.91%), ischemic heart disease (10%), renal diseases 
(1.82%) and cancers (1.82%) followed these, respectively. 
We compared our results with larger cohorts. Turkiye 
Romatizma Arastirma ve Savas Dernegi [TRASD] (Turkish 
League Against Rheumatism) data base comprising 1,381 
Turkish patients with AS revealed the rate of comorbidities 
as follows: peptic ulcer (8.8%), hypertension (7.5%), 
cardiac disease (3.6%) and diabetes mellitus (3%) [16]. High 
percentage of comorbidities in our series is remarkable. This 
may be due to our patient selection criteria. Our group of 
patients included mostly severe ones who require regular 
controls in a tertiary hospital. The frequency of comorbidities 
in AS patients differs from one country to another. This 
situation may be explained by including genetic factors and 
geographic differences in lifestyles and eating behaviors.  In 
emAR study from another Mediterranean country, Spain, 
the most common conditions were reported as hypertension 
(17.4%), peptic ulcer (6.8%) and diabetes mellitus (6.1%) 
[17]. In a study which was conducted in United Kingdom, 
prevalence of overall comorbidities was reported as 50%. 
The most common was hypertension with a rate of 17% [18]. 
In a study performed in another European country, Sweden, 
the rates of comorbidities were lower than in our series. 
Ischemic heart disease was seen in 2.2% of the patients. 
Hypertension (1.98%) and diabetes mellitus (1.41%) 
followed it, respectively [4].  In a study from Taiwan, the 
most frequent comorbidities in the patients with AS were 
reported as hypertension (16.4%), peptic ulcer (13.9%) and 
headache (10.2%) [3]. 
Ankylosing spondylitis involves frequently the axial 
skeleton, and peripheral joint involvement is observed 
in 20–35 % of patients [19].  In agreement with these 
observations, peripheral joint involvement was 27.27% in 
our patients. In 66.67% the hips, in 56.67% the knees, in 
10% the shoulders and in 6.67% the ankles were influenced. 
In a study of Brunner et al. [20] which was conducted on 
1177 AS patients in Switzerland, peripheral involvement 
was reported as 31.5 %. In 58% of the cases the hips, in 
35% the shoulders, and in 31% the knees were affected. 
Rate of shoulder involvement was much higher than ours. 
In REGISPONSER study conducted on 1,385 Spanish 
patients with AS, frequency of peripheral involvement was 
found as 17.4% [21]. In emAR study, peripheral arthritis 
was reported in 54.8% of the patients [17]. They explained 
this high percentage by the dominance of psoriatic arthritis 
or undifferentiated spondyloarthritis in their series. Tayel et 
al. [22] reported the peripheral joint involvement as 32% in 
Indian patients with AS. 
We found that the frequency of comorbidities was 
higher in the patients with peripheral involvement when 
compared with those without peripheral involvement. To our 
knowledge,  this is the first study to demonstrate an association 
between the presence of peripheral joint involvement and 
comorbidities in AS patients. This association might result 
from the disease process or the treatment. Peripheral arthritis 
is associated with inflammation. Inflammation may also 
initiate or worsen comorbid diseases such as ischemic heart 
disease, osteoporosis, depression and diabetes. Additionally, 
multiple drug use due to peripheral arthritis is associated 
with increased potential for comorbid conditions such as 
peptic ulcer and hypertension. Due to the cross-sectional 
design of the study, we could not determine the cause-effect 
relationships. Further longitudinal studies are needed. 
The present study investigated the effect of comorbidities 
on HRQoL including physical, social, and emotional 
functions, and pain. The relationship between the presence of 
comorbidities and disease activity, functional status, and pain 
was evaluated. Presence of comorbidities was found to be 
associated with disease activity, functional status and pain. 
This might result from increased drug use due to worsening of 
the disease. Additionally, we demonstrated that comorbidities 
had a significant negative impact on HRQoL in terms of 
pain, physical mobility, and energy. However HRQoL 
domains including sleep, social and emotional functions 
were not affected by comorbidities. In the literature, there are 
a few studies which assess the relation of comorbidities with 
HRQoL and clinical parameters in AS patients. In the study 
of Stolwijk et al. [8], where the comorbidities were evaluated 
by using Self-administered Comorbidity Questionnaire, 
it was found that the comorbidities were correlated with 
functional disability, higher disease activity and impaired 
HRQoL in the patients with AS. Similarly, Ariza-Ariza et 
al. [23] reported lower HRQoL scores in terms of mobility, 
self-care, pain and psychological status in Spanish patients 
with comorbidities. Boonen et al. [24] indicated functional 
impairment and deterioration in physical and social functions, 
vitality and mental health domains of HRQoL in AS patients 
with comorbidities. In the study of Salaffi et al. [25], where 
disease activity was determined by using BASDAI, it was 
reported that the patients with comorbidities had severe 
disease. 
Our study has several limitations. First one is relatively 
small number of subjects. And secondly, we did not 
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review the medication used which can be associated with 
comorbidities. Third, cause-effect relationships cannot be 
determined. For this reason, a longitudinal study is necessary. 
The present study also investigated the effect of age, 
gender and BMI on comorbidities in the patients with 
AS. We found no impact of these parameters on presence 
of comorbidities. It was unexpected that frequency 
of comorbidities did not increase with age. In normal 
population, comorbidities increase with age; however in 
patients with AS, due to the effects of disease activity, there 
may not be a direct association between comorbidities and 
increasing age. Kang et al. [3] indicated a gender difference 
in comorbidities associated with AS, however,  they did not 
report which comorbidities were common in men or women. 
To our knowledge, our study was to first to investigate 
impact of BMI on comorbidities in the patients with AS. 
In conclusion, comorbidities are associated with more 
active and severe disease and functional impairment in the 
patients with AS. They have a negative impact on HRQoL 
in terms of physical functioning, and vitality. Monitoring of 
comorbidities should be involved in clinical practice. Regular 
monitoring of renal functions and hypertension is needed 
for the patients on long term NSAID therapy. Comorbidities 
should be detected and taken into consideration in the choice 
of medical treatment.   
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